Publications

2019

Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, et al. p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell. 2019;35(1):46-63.e10.
Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing . J Clin Microbiol. 2019;57(5).
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(Suppl_8):viii16-viii22.
Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, et al. AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast. NPJ Breast Cancer. 2019;5:10.
Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, et al. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat Genet. 2019;51(10):1427-1428.
Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, et al. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019;14(6):e0218660.
Kyriakides K, Selkin G, Selkin B, Iwenofu H, Magro CM. Chronic Fibrosing Vasculitis in the Setting of Still Disease. J Clin Rheumatol. 2019;25(7):e127-e130.
Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, et al. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv. 2019;1(1):vdz004.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700